Business Wire

WEP-CLINICAL

6.7.2020 13:02:10 CEST | Business Wire | Press release

Share
WEP Clinical Partners With Nabriva Therapeutics for the Named Patient Supply of XENLETA® (lefamulin)

WEP Clinical (WEP), a specialist pharmaceutical services company, has signed an exclusive agreement with Nabriva Therapeutics (Nabriva) to supply XENLETA® (lefamulin) on a named patient or expanded access basis. The Named Patient Program (NPP) is designed to ensure that physicians, contingent on meeting the necessary eligibility criteria and receiving approval, can request IV or oral XENLETA on behalf of patients who live in certain countries where it is not yet available.

XENLETA was discovered and developed by Nabriva (NASDAQ: NBRV), a commercial-stage biopharmaceutical company focused on commercialization and development of anti-infective agents. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by susceptible microorganisms. XENLETA is the first and only oral and IV pleuromutilin empiric antibiotic that acts against the pathogens that commonly cause CABP.

Nabriva announced on May 29th that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of XENLETA for the treatment of community-acquired pneumonia (CAP) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of CAP or when these have failed. The CHMP opinion will be reviewed by the European Commission (EC), which has the authority to approve medicines for all 28 countries of the European Union, Norway, Iceland, and Liechtenstein. A regulatory decision is anticipated during the second half of 2020.

Under the terms of the NPP, XENLETA will be made available in two formulations - 150mg injection for intravenous administration and 600mg oral tablets - using named patient or expanded access managed by WEP to enable healthcare professionals to access XENLETA for patients that have an unmet clinical need. Once a request is approved, WEP will manage the distribution of XENLETA to the treating physician and will provide any necessary follow-up support and services.

About WEP Clinical

Established in 2008, WEP Clinical is a specialist services company that works with drug developers to help patients and physicians gain early access to medicines when no other treatment options are available. We have offices located in the UK, US, Portugal and Ireland and possess all the necessary licenses allowing us to meet drug access and distribution needs across all regions, worldwide. We are passionate about helping those in need. For more information, please visit www.wepclinical.com .

About Nabriva Therapeutics

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). XENLETA was discovered in Nabriva Therapeutics laboratories in Vienna, Austria. For more information, please visit www.nabriva.com .

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

XENLETA is a pleuromutilin antibacterial indicated for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae.

USAGE

To reduce the development of drug-resistant bacteria and maintain the effectiveness of XENLETA and other antibacterial drugs, XENLETA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

XENLETA is contraindicated in patients with known hypersensitivity to XENLETA or pleuromutilins.

XENLETA tablets are contraindicated for use with CYP3A4 substrates that prolong the QT interval.

WARNINGS AND PRECAUTIONS

XENLETA has the potential to prolong the QT interval. Avoid XENLETA in patients with known QT prolongation, ventricular arrhythmias, and patients receiving drugs that may prolong the QT interval.

Based on animal studies, XENLETA may cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus and to use effective contraception.

Clostridium difficile-associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including XENLETA, with severity ranging from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs.

ADVERSE REACTIONS

The most common adverse reactions (≥2%) for (a) XENLETA Injection are administration site reactions, hepatic enzyme elevation, nausea, hypokalemia, insomnia, and headache and (b) XENLETA Tablets are diarrhea, nausea, vomiting, and hepatic enzyme elevation.

USE IN SPECIFIC POPULATIONS

In patients with severe hepatic impairment, reduce the dosage of XENLETA Injection to 150 mg infused over 60 minutes every 24 hours. XENLETA Tablets are not recommended in patients with moderate or severe hepatic impairment due to insufficient information to provide dosing recommendations.

Avoid XENLETA Injection and Tablets with concomitant strong or moderate CYP3A or P-gp inducers. Monitor for reduced efficacy of XENLETA.

Avoid XENLETA Tablets with strong CYP3A or P-gp inhibitors.

Monitor for adverse reactions of sensitive CYP3A substrates administered with XENLETA Tablets.

XENLETA has not been studied in pregnant women. Verify pregnancy status in females prior to initiating XENLETA and advise females to use contraception during treatment and for 2 days after the final dose. Lactating women should pump and discard milk for the duration of treatment with XENLETA and for 2 days after the final dose.

To report SUSPECTED ADVERSE REACTIONS, or administration during pregnancy, contact Nabriva Therapeutics US, Inc. at 1-855-5NABRIVA or FDA at 1-800-FDA-1088 or

https://www.fda.gov/safety/medwatch

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Grand Prix ACF AutoTech 2027: Applications Open for the 10th Edition18.11.2026 13:00:00 CET | Press release

Since 2018, the competition’s 52 finalists have raised more than €700 million The Automobile Club de France (ACF) and ESSEC Alumni are launching the 10th edition of the Grand Prix ACF AutoTech, the leading competition for automotive and mobility startups. French and international startups can apply until November 27, 2026 at 11:59 p.m. (CET) at www.grandprixacfautotech.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118772168/en/ Jury members and former finalist startups for the launch of 10th Edition of Grand Prix ACF AutoTech (c) Quentin Vaquez Since 2018, the competition has selected 52 finalists, including Chargemap, Hiflow, ChargeGuru and Geolith, who have together raised more than €700 million. Only 6 have failed: a survival rate of nearly 90%. The 2026 edition rewarded Altrove (Grand Prix ACF), Bloomineral (ACF Pioneer Prize and GreenTech Mention) and IoT.bzh (Industrialization Prize). “Ten editions is an achie

New TOURISE Report Reveals How Traveler Expectations Are Changing the Rules for Global Tourism18.11.2026 13:00:00 CET | Press release

Report urges tourism leaders to focus on high-value trips, not just high-spending visitors, and measure benefits retained by local communities Nearly 150 million more households could afford international leisure travel by 2030, including almost 110 million in Asia Pacific 59% of surveyed AI users turn to AI for travel information, but only 12% of consumers in a separate survey trust it to make decisions independently 43% of travelers surveyed across 35 markets planned to avoid overcrowded destinations in 2026 Changing traveler priorities are reshaping global tourism, influencing where people go, how they spend and what they value most from their journeys. A new report released by TOURISE, The Future Traveller, explores these shifts and what they mean for the industry through 2030. Developed in collaboration with Euromonitor International, the report draws on consumer surveys and perspectives from industry leaders. The report finds that travel decisions are increasingly shaped by the p

Rockwell Automation Signs Definitive Agreement to Acquire AGILOX18.11.2026 13:00:00 CET | Press release

This acquisition accelerates our physical AI strategy and creates a comprehensive autonomous mobile robot portfolio Rockwell Automation, Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and digital transformation, today announced it has signed a definitive agreement to acquire Austria-based AGILOX, a maker of high-end autonomous mobile robots (AMRs) that are driven by self-developed artificial intelligence and swarm networking technology. Together, AGILOX’s proven forklift AMR portfolio and OTTO by Rockwell Automation’s flatbed AMR platform will create a comprehensive autonomous material movement offering, elevating AGILOX from a best-in-class point solution to a cornerstone of a world-class comprehensive production logistics capability. The acquisition will combine OTTO's strong presence in North America with AGILOX's established footprint across Europe. AGILOX will gain access to Rockwell's deep customer relationships in strategic verticals like consum

Ant International Pioneers PayNow Deep-Linking for E-Commerce, Explores Government Services Use Case Under MAS’ PayNow Gen2 Initiative18.11.2026 12:40:00 CET | Press release

Ant International’s Antom is the first to implement PayNow deep-link for e-commerce, via Lazada, with ~9% uplift in payment success rate.2C2P by Antom is collaborating with the Government Technology Agency of Singapore (GovTech Singapore) to explore PayNow deep-linking capabilities through GovWallet.Ant International will further explore supporting PayNow Gen2, including through its global wallet gateway Alipay+ expanding SGQR+ interoperability, and introducing AI-powered digital services for consumers and merchants. Ant International is the first partner under the Monetary Authority of Singapore (MAS)’s PayNow Generation 2.0 launch to introduce live use cases for deep-linking for e-commerce and digital government services. The launch is enabled by Antom, its global merchant payment and digitisation services provider, and Antom’s Southeast Asia subsidiary, 2C2P by Antom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202611183

IFF Opens Its First Forest Lab in Brazil's Atlantic Forest to Advance Fragrance and Beauty Innovation18.11.2026 12:30:00 CET | Press release

New lab at Legado das Águas, Brazil’s largest private Atlantic Forest reserve, connects biodiversity with scientific discovery and innovation in perfumery and beauty. IFF (NYSE: IFF) — a global leader in flavors, fragrances and health and biosciences — today opened its first Forest Lab at Legado das Águas, Brazil's largest private Atlantic Forest reserve. The lab is the next step in the bioprospecting partnership IFF announced in August 2025 with Reservas Votorantim (rV), the green economy division of Brazilian investment firm Votorantim SA, which manages the reserve. Spanning 31,000 hectares and home to nearly 1,000 plant species, Legado das Águas now hosts biodiversity research, scent discovery, perfumery and beauty innovation in one place, while supporting rV's conservation work. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117495933/en/ A scientist in the new IFF Brazil Forest Lab at Legado das Águas, the country’s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye